araag2/HINT huggingface dataset:
Clinical trial NCT01474551 (phase 2, status: terminated)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: vemurafenib
SMILES: CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age >18 years old.

          -  Histologic proof of melanoma reviewed and confirmed by MSKCC.

          -  A confirmed EBRAFV600E or KBRAFV600K mutation.

          -  Stage IV melanoma, or advanced stage III not curable by surgery. Patients with active
             CNS metastases will be allowed on the study.

          -  Measurable disease by RECIST v1.1.

          -  ECOG performance status 3 or 4. The basis for the grading of performance is strict;
             there must be clear justification of the performance status grade (e.g. patient is
             confined to bed > 50% of time, or cannot carry out ADLs, or is otherwise disabled by
             burden of disease such as requiring supplemental O2).

          -  Patients must be able to swallow pills

          -  Adequate hematologic, hepatic and renal function as defined by the following:

          -  Absolute Neutrophil Count ≥ 1.0 x 109/L

          -  Hemoglobin ≥8.0g/dL, occasional transfusions are acceptable as vemurafenib does not
             have significant hematologic toxicities.

          -  Total bilirubin ≤2.0x the upper limit of normal, ≤3.0x the upper limit of normal if
             the patient has Gilbert's Syndrome.

          -  Alkaline phosphatase ≤2.0x the upper limit of normal.

          -  AST and ALT ≤2.0x the upper limit of normal.

          -  Serum creatinine ≤ 1.5x the upper limit of normal.

        Exclusion Criteria:

          -  Uveal melanoma as primary.

          -  Concurrent chemotherapy, immunotherapy, or radiotherapy.

          -  Prior treatment with a RAF inhibitor. Other prior chemotherapy, immunotherapy, or
             radiotherapy will be allowed including prior treatment with a MEK inhibitor Patients
             must have had complete recovery from any adverse events or toxicities of prior
             cancer-directed therapies.

          -  Pregnant or lactating women.

          -  A second active malignancy. Prior malignancy will be allowed as long as the patient is
             known to be free of disease for at least 2 years. Patients with indolent B-cell
             malignancies will not be eligible.

          -  QTc interval > 500 msec.
Clinical trial NCT00635726 (phase 2, status: terminated)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: methotrexate, vinblastine, doxorubicin, cisplatin, cisplatin, gemcitabine
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed transitional cell carcinoma of the urinary
             bladder.

          -  Metastatic or locally advanced disease.

          -  No prior chemotherapy.

          -  Performance status (World Health Organization) 0-2.

          -  Measurable or evaluable disease.

          -  Measurable disease is defined as at least 1 unidimensional measurable lesion

             ≥20 mm by conventional techniques or 1 bidimensionally measurable lesion ≥ 20 X 10 mm.
             Lesions that are smaller or uni- or bidimensionally unmeasurable are considered as
             evaluable disease.

          -  Adequate liver (bilirubin ≤ 1.5 Upper Normal Limit, serum glutamate-pyruvate
             aminotransferase/serum glutamic pyruvic transaminase ≤ 2 Upper Normal Limit, ALP ≤ 2.5
             Upper Normal Limit), renal (creatinine ≤ 1.5 Upper Normal Limit) and bone marrow
             (absolute neutrophil count ≥ 1,500/mm3, platelet count ≥ 100,000/mm3) function.

          -  Life expectancy > 3 months.

          -  Patients must be able to understand the nature of this study and give written informed
             consent.

        Exclusion Criteria:

          -  History of serious cardiac disease (unstable angina, severe congestive heart failure,
             myocardial infarction within the previous 6 months, ventricular arrhythmias).

          -  Second primary malignancy, except for non-melanoma skin cancer and in situ cervical
             cancer.

          -  Active infection.

          -  Uncontrolled inflammation.

          -  Pregnant or lactating women.

          -  Psychiatric illness or social situation that would preclude study compliance.
Clinical trial NCT01111656 (phase 2, status: completed)
Conditions: relapsing-remitting multiple sclerosis
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: interferon beta-1b group, interferon beta-1b/atorvastatin group
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Successful completion of the SWABIMS study

          -  Written informed consent

        Exclusion Criteria

          -  Any disease other than multiple sclerosis that would better explain the patient's
             signs and symptoms

          -  Secondary progressive MS

          -  Uncontrolled severe medical disorder

          -  Participation in any other studies
Clinical trial NCT00598507 (phase 2, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: zk-epo
SMILES: C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed Malignant Melanoma.

          -  Unresectable Stage III or Stage IV disease.

          -  At least 1 measurable lesion.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

          -  Adequate function of major organs and systems as measured by the following criteria:

        Bone Marrow:

          -  Hemoglobin ≥ 10 g/dL

          -  White blood count (WBC) ≥ 3,000/mm^3

          -  Absolute neutrophil count (ANC) ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic:

          -  Bilirubin within 1.5 times normal limit

          -  aspartate transaminase (AST)/Alanine aminotransferase (ALT) ≤ 5 times the upper limit
             of normal (ULN)

        Renal:

          -  Creatinine ≤ 2 mg/dL

        Cardiovascular:

          -  No New York Heart Association (NYHA) class III or IV Congestive heart failure

          -  No unstable angina pectoris

          -  No arrhythmia needing continuous treatment

        Nervous system:

          -  No Grade ≥ 2 peripheral neuropathy

        Exclusion Criteria:

          -  More than 2 previous chemotherapy regimens.

          -  Any prior treatment with Epothilones, Epothilone analogues, taxanes, or vinca
             alkaloids.

          -  Any progressive central nervous system (CNS) metastatic disease. Patients with CNS
             metastases may be allowed if stable for 8 weeks or more and patient is neurologically
             intact and off of steroids. The stability must be documented by MRI/CT over a period
             of 8 weeks or greater.

          -  Any radiotherapy, chemotherapy, or immunotherapy within 3 weeks prior to first dose of
             ZK-Epo. If patients were previously on temozolomide with extended dose schedule, they
             must be off 1 week prior to the first dose of ZK-Epo.
Clinical trial NCT01373554 (phase 2, status: completed)
Conditions: non-alcoholic fatty liver disease
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: placebo, oltipraz
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=C(SSC1=S)C1=CN=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients over 18, under 75 years of age

          -  Patients with non-alcoholic fatty liver disease

        Exclusion Criteria:

          -  Over 2 ratio of AST to ALT

          -  Type 1 diabetes mellitus (insulin-dependent diabetes mellitus)

          -  Disorder in liver function with an exception of non-alcoholic fatty liver (e.g. Virus
             infection, biliary atresia, autoimmune hepatitis and etc.)

          -  Patients who have been taken drugs induced fatty liver for over 3 month within 1 year
             of participation in this study; amiodarone, tamoxifen, methotrexate, tetracyclines,
             glucocorticoids, anabolic steroids, over usual dose of estrogen for hormone
             replacement therapy and valproate

          -  Patients who has been taken any medications that could affect the treatment for
             non-alcoholic steatohepatitis: insulin, insulin sensitizer(metformin,
             thiazolidinedione), high dose of vitamin E, high dose of UDCA, pentoxifylline, SAM-e,
             Betaine, types of Statin, types of fibrate and orlistat

          -  Patients who had a Bariatric surgery less than 6 month prior to the participation in
             the study

          -  Patients who are judged by investigator that participation of the study is difficult
             due to disease as follow; hepatic cirrhosis, Wilson's disease, malignant tumor,
             serious metabolic disease, severe renal disease, severe pulmonary disease, severe
             cardiovascular disease, severe nervous disease/psychiatric disorder, muscle disease
             and etc

          -  Any history of immune disorder which affect the changes in cytokine:

        inflammatory bowel disease, autoimmune thrombocytopenic purpura, system lupus
        erythematosus, autoimmune hemolytic anemia, severe psoriasis, rheumatic arthritis and etc

          -  Patients who have received treatment that may affect liver function within 1 month
             prior to the participation in the study

          -  Patient who has been administered other investigational product within 1 month prior
             to the participation in the study

          -  Patient who is not allowed to get MRS test: pacemaker, shunt and etc

          -  Pregnant or nursing women

          -  Patient who considered ineligible for participation in the study as Investigator's
             judgment
Clinical trial NCT00303927 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed pancreatic cancer

               -  Stage IV disease

          -  Measurable disease (≥ 1 cm or > 10 mm lesion(s) by spiral CT scan)

          -  Disease progression after ≥ 1 gemcitabine-based treatment regimen for
             advanced/metastatic disease

          -  Patient carries the double tandem repeat (S/S) variant of the thymidylate synthase
             gene enhancer region (TSER)

          -  No active CNS metastases (indicated by clinical symptoms, cerebral edema, steroid
             requirement, or progressive growth)

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  AST/ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if attributable to liver
             metastases)

          -  Total bilirubin ≤ 1.5 times ULN

          -  Creatinine normal OR creatinine clearance > 50 mL/min

          -  Fertile patients must use effective contraception during and for 30 days after
             completion of study treatment

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Asymptomatic HIV infection allowed

          -  No recent or ongoing clinically significant gastrointestinal disorder (e.g.,
             malabsorption, bleeding, inflammation, emesis, or diarrhea > grade 1)

          -  Able to swallow capecitabine tablets

          -  No known hypersensitivity to fluorouracil

          -  No dihydropyrimidine dehydrogenase (DPD) deficiency

          -  No clinically significant cardiac disease (e.g., congestive heart failure, symptomatic
             coronary artery disease, or cardiac arrhythmias not well controlled with medication)

          -  No myocardial infarction within the past 6 months

          -  No serious, uncontrolled, concurrent infection(s)

          -  No prior unanticipated severe reaction to fluoropyrimidine therapy

          -  No other malignancy within the past 5 years except cured nonmelanoma skin cancer or
             treated carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 3 weeks since prior chemotherapy

          -  No prior capecitabine except in the adjuvant setting

          -  At least 3 weeks since prior radiotherapy or major surgery

          -  At least 4 weeks since prior participation in any investigational drug study

          -  At least 4 weeks since prior sorivudine or brivudine

          -  No concurrent sorivudine or brivudine

          -  No concurrent cimetidine or azidothymidine (AZT)

          -  Concurrent radiotherapy for bone pain allowed to a limited field provided ≥ 1
             indicator lesion remains outside of the field

          -  No other concurrent chemotherapy or immunotherapy
Clinical trial NCT00003847 (phase 2, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: biricodar dicitrate, doxorubicin hydrochloride, vincristine sulfate
SMILES: COC1=CC(=CC(OC)=C1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)OC(CCCC1=CN=CC=C1)CCCC1=CN=CC=C1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed oat cell or intermediate type small cell
        lung cancer Patients must have received prior therapy, with the following: Documented
        disease progression (new lesions or increased lesion size) after front line therapy No more
        than 1 prior chemotherapy regimen Complete or partial response to initial chemotherapy
        (must have lasted more than 60 days after end of therapy before relapse occurred)
        Bidimensionally measurable disease At least one lesion outside of irradiation field Pleural
        effusions are not measurable No brain or bone metastases as only measurable site No
        uncontrolled brain or other CNS metastases (surgical excision and/or radiotherapy)

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not
        specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at
        least 100,000/mm3 Hepatic: AST no greater than 2 times upper limit of normal Bilirubin no
        greater than 1.5 mg/dL Renal: Creatinine less than 1.3 mg/dL OR Creatinine clearance
        greater than 60 mL/min Cardiovascular: Cardiac ejection fraction greater than 45% by MUGA
        or echocardiogram No uncontrolled ventricular arrhythmias Other: Not pregnant or nursing
        Negative pregnancy test Fertile patients must use effective contraception No senile
        dementia or psychiatric disorders Not concurrent serious infection No major seizure
        disorder No grade 3 neuropathies No spinal cord compression No other concurrent unstable
        medical condition No other prior malignancies within past 5 years, except: Adequately
        treated basal or squamous cell skin cancer Any carcinoma in situ

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics No prior doxorubicin or vincristine as first line treatment for small cell
        lung cancer Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to greater
        than 50% of bone marrow At least 30 days since prior radiotherapy Surgery: Not specified
        Other: No concurrent experimental drugs or anticancer therapies Concurrent medication for
        chronic medical conditions allowed (e.g., hypertension) No concurrent cimetidine,
        phenothiazines, phenobarbital, carbamazepine, troleandomycin, sulfinpyrazone, rifampin,
        Dilantin, and cyclosporine-A (or other P-gp inhibitors)
Clinical trial NCT00284518 (phase 2, status: completed)
Conditions: benign prostatic hyperplasia
ICD codes: N40.0, N40.1
Drugs: normal saline
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Lower urinary tract symptoms due to benign prostatic hyperplasia

          -  Enlarged prostate volume by rectal ultrasound

        Exclusion Criteria:

          -  Previous prostate surgery

          -  Previous or current diagnosis of prostate cancer

          -  Use of other medications for the treatment of prostatic hyperplasia

          -  Urinary tract infection
Clinical trial NCT01428661 (phase 2/phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: tasimelteon, placebo
SMILES: [H][C@@]1(CN=C(O)CC)C[C@@]1([H])C1=C2CCOC2=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with diagnosis of MDD, single or recurrent episode, according to DSM-IV TR
             criteria;

          -  Current episode ≥4 weeks and ≤1 year;

          -  CGI-Severity score ≥4 at screening and baseline.

        Exclusion Criteria:

          -  Lifetime history of bipolar disorder (I or II), schizophrenia, schizoaffective
             disorder, eating disorder, or obsessive-compulsive disorder;

          -  Any other current Axis I (except general anxiety disorder as long as it is not
             considered the primary disorder) or Axis II disorder;

          -  A positive test for drugs of abuse at the screening visit and/or history of drug or
             alcohol abuse/dependence as defined in DSM-IV TR, Diagnostic Criteria for Drug and
             Alcohol Abuse and Dependence, within the past 12 months;

          -  Formal psychotherapy within 3 months of the screening visit. General supportive
             psychotherapy is acceptable;

          -  Participation in a previous tasimelteon trial. Other protocol-defined
             inclusion/exclusion criteria may apply
Clinical trial NCT00635323 (phase 2, status: completed)
Conditions: carcinoma, hepatocellular
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: irinotecan plus capecitabine
SMILES: CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Asian subjects with histologically or cytologically confirmed hepatocellular carcinoma

          -  Inoperable disease (unable to completely remove surgically, presence of extra-hepatic
             disease, main portal vein or hepatic vein involvement)

          -  Eastern Cooperative Oncology Group performance status of ?2

        Exclusion Criteria:

          -  Decompensated cirrhosis or stage C (Index>10) according to the Child-Pugh
             Classification

          -  Current history of chronic diarrhoea

          -  Reproductive potential not using adequate contraceptive measures
Clinical trial NCT00421434 (phase 2/phase 3, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: nitazoxanide, ribavirin, ribavirin
SMILES: CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥18 years.

          -  Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme
             immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification
             of HCV RNA.

          -  Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral
             hepatitis.

          -  HCV genotype 4.

        Exclusion Criteria:

          -  Patients who have previously failed to respond to ≥12 weeks of peginterferon-ribavirin
             combination therapy.

          -  Females who are either pregnant, breast-feeding or not using birth control and are
             sexually active.

          -  Males whose female partners are pregnant.

          -  Patients with other causes of liver disease (i.e., autoimmune hepatitis, decompensated
             liver disease).

          -  Patients co-infected with hepatitis A virus, hepatitis B virus or hepatitis D virus.

          -  Patients with a history of alcoholism or with an alcohol consumption of >40 grams per
             day.

          -  Patients with hemoglobinopathies (i.e., thalassemia major, sickle-cell anemia).

          -  Patients with any concomitant condition that, in the opinion of the investigator,
             would preclude evaluation of response or make it unlikely that the contemplated course
             of therapy and follow-up could be completed.

          -  History of hypersensitivity or intolerance to any of the excipients comprising the
             nitazoxanide tablets, peginterferon alfa-2a injectionable solution or ribavirin
             tablets.
Clinical trial NCT00077025 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gefitinib, anastrozole
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Female postmenopausal patients aged 18 years or older with newly diagnosed metastatic
             breast cancer.

          -  Patients with recurrent disease during or after adjuvant tamoxifen or patients who are
             hormone therapy naïve are eligible for this trial.

          -  A paraffin embedded tumor tissue block or slides from either the metastatic or primary
             tumor site is required.

        Exclusion Criteria:

          -  Patients cannot be on hormone replacement therapy while on study.

          -  Prior chemotherapy received for metastatic disease is not allowed.

          -  Previous treatment with tyrosine kinase inhibitors or aromatase inhibitors is not
             allowed.

          -  Patients who have evidence of an active interstitial lung disease are not eligible.